Percutaneous catheter-based repeat revascularization in patients with previous PCI or CABG: a comprehensive review of the evidence

Abstract

Repeat revascularization after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is one of the most common long-term complications which warrants continuous clinical follow up. Re-interventions negatively impact long-term survival in patients with coronary artery disease. The repeat revascularization after PCI can be either a target lesion revascularization (stent thrombosis/in-stent restenosis) or a revascularization of native coronary artery after PCI (target vessel revascularization/non-target vessel revascularization). The EVENT registry reports that repeat revascularization rates in patients undergoing PCI is 12% in the first year of follow up. Repeat revascularization with additional stent deployment increases the rate of stent thrombosis and restenosis, thereby leading to recurrent ischemic events. Repeat revascularization after CABG can be either in the early postoperative period or later due to native disease progression or late graft stenosis. The need for re-intervention after surgical or percutaneous revascularization is inevitable and is dependent on modifiable and non-modifiable risk factors.

Keywords

Revascularization / percutaneous cardiac intervention / coronary artery / coronary artery bypass grafting

References

[1] Alfonso F,Rivero F.Current treatment of in-stent restenosis.J Am Coll Cardiol2014;63:2659-73

[2] Royse AG,Ou-Young J,Canty DJ.21-year survival of left internal mammary artery-radial artery-Y graft.J Am Coll Cardiol2018;72:1332-40

[3] Patel NJ,Atti V.Drug-eluting stents versus bare-metal stents in saphenous vein graft intervention.Circ Cardiovasc Interv2018;11:e007045

[4] Kulik A,Jneid H.American Heart Association Council on Cardiovascular Surgery and AnesthesiaSecondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association.Circulation2015;131:927-64

[5] Neumann FJ,Ahlsson A.ESC Scientific Document Group2018 ESC/EACTS guidelines on myocardial revascularization.Eur Heart J2019;40:87-165

[6] Stolker JM,Kennedy KF.Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) InvestigatorsRepeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.Circ Cardiovasc Interv2012;5:772-82

[7] Palmerini T,Biondi-Zoccai G.Mortality following nonemergent, uncomplicated target lesion revascularization after percutaneous coronary intervention: an individual patient data pooled analysis of 21 randomized trials and 32,524 patients.JACC Cardiovasc Interv2018;11:892-902

[8] Byrne RA,Kastrati A.Stent thrombosis and restenosis: what have we learned and where are we going?.Eur Heart J2015;36:3320-31 PMCID:PMC4677274

[9] Schühlen H,Mehilli J.Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement.Am Heart J2004;147:317-22

[10] Cutlip DE,Ho KK.Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.Circulation2001;103:1967-71

[11] Rozemeijer R,Leenders G.Incidence, angiographic and clinical predictors, and impact of stent thrombosis: a 6-year survey of 6,545 consecutive patients.Neth Heart J2019;27:321-9 PMCID:PMC6533324

[12] Stone GW,Cox DA.ACUITY InvestigatorsBivalirudin for patients with acute coronary syndromes.N Engl J Med2006;355:2203-16

[13] Wiviott SD,McCabe CH.TRITON-TIMI 38 InvestigatorsPrasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med2007;357:2001-15

[14] Wallentin L,Budaj A.PLATO InvestigatorsTicagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med2009;361:1045-57

[15] Mauri L,Yeh RW.DAPT Study InvestigatorsTwelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med2014;371:2155-66 PMCID:PMC4481318

[16] Bangalore S,Fusaro M.Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.Circulation2012;125:2873-91

[17] Zhao LP,Wang L.Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.Coron Artery Dis2015;26:5-10

[18] Taniwaki M,Zaugg S.The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study.Eur Heart J2015;36:2167-76

[19] Fujii K,Kobayashi Y.Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis.Circulation2004;109:1085-8

[20] Alfonso F,Cardenas A,Cuevas C.Optical coherence tomography: from research to clinical application.Minerva Med2012;103:441-64

[21] Angioi M,Rodriguez R.Increased C-reactive protein levels in patients with in-stent restenosis and its implications.Am J Cardiol2001;87:1189-93

[22] Kedhi E,Mcfadden E.Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.Lancet2010;375:201-9

[23] Harjai KJ,Pinkosky B,Orshaw P.Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.J Interv Cardiol2013;26:153-62

[24] Alfonso F,Dutary J.RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology)Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]).JACC Cardiovasc Interv2012;5:728-37

[25] Alfonso F,García Del Blanco B.under the auspices of the Interventional Cardiology Working Group of the Spanish Society of CardiologyEverolimus-eluting stents in patients with bare-metal and drug-eluting in-stent restenosis: results from a patient-level pooled analysis of the RIBS IV and V trials.Circ Cardiovasc Interv2016;9:e003479

[26] Glaser R,Faxon DP.Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention.Circulation2005;111:143-9

[27] Stone GW,Lansky AJ.PROSPECT InvestigatorsA prospective natural-history study of coronary atherosclerosis.N Engl J Med2011;364:226-35

[28] Alexopoulos D,Davlouros P.Mechanisms of nonfatal acute myocardial infarction late after stent implantation: the relative impact of disease progression, stent restenosis, and stent thrombosis.Am Heart J2010;159:439-45

[29] Bayturan O,Nicholls SJ.Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol.J Am Coll Cardiol2010;55:2736-42

[30] Delhaye C,Lemesle G.Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.Cardiovasc Revasc Med2009;10:144-50

[31] Virmani R,Burke AP,Schwartz SM.Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions.Arterioscler Thromb Vasc Biol2000;20:1262-75

[32] Takano M,Inami S.In vivo comparison of optical coherence tomography and angioscopy for the evaluation of coronary plaque characteristics.Am J Cardiol2008;101:471-6

[33] Palmerini T,Della Riva D.Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting.J Am Coll Cardiol2017;69:2011-22

[34] Thielmann M,Jaeger BR.Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery.Eur J Cardiothorac Surg2006;30:117-25

[35] Jain U.Myocardial infarction during coronary artery bypass surgery.J Cardiothorac Vasc Anesth1992;6:612-23

[36] Chaitman BR,Sheffield LT.Use of survival analysis to determine the clinical significance of new Q waves after coronary bypass surgery.Circulation1983;67:302-9

[37] Thielmann M,Schmermund A.Diagnostic discrimination between graft-related and non-graft-related perioperative myocardial infarction with cardiac troponin I after coronary artery bypass surgery.Eur Heart J2005;26:2440-7

[38] Davierwala PM,Leontyev S,Borger MA.Impact of expeditious management of perioperative myocardial ischemia in patients undergoing isolated coronary artery bypass surgery.Circulation2013;128:S226-34

[39] Dauerman HL,Sellke FW.Intracoronary thrombolysis in the treatment of graft closure immediately after CABG.Ann Thorac Surg1996;62:280-3

[40] Breuer M,Gansera B,Weingartner J.Intraoperative local fibrinolysis as emergency therapy after early coronary artery bypass thrombosis1.Eur J Cardiothorac Surg1999;15:266-70

[41] Schömig A,Antoniucci D.Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial InvestigatorsMechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial.JAMA2005;293:2865-72

[42] Kim CB.Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis.Circulation1993;88:2426-36

[43] Sergeant P,Meyns B,Jashari R.First cardiological or cardiosurgical reintervention for ischemic heart disease after primary coronary artery bypass grafting1.Eur J Cardiothorac Surg1998;14:480-7

[44] Sabik JF 3rd,Gillinov AM,Lytle BW.Occurrence and risk factors for reintervention after coronary artery bypass grafting.Circulation2006;114:I454-60

[45] Parasca CA,Milojevic M.SYNTAX InvestigatorsIncidence, characteristics, predictors, and outcomes of repeat revascularization after percutaneous coronary intervention and coronary artery bypass grafting: the SYNTAX trial at 5 years.JACC Cardiovasc Interv2016;9:2493-507

[46] Borowski A,Ghodsizad A.Coronary artery disease progression in patients who need repeat surgical revascularisation: the surgeon's point of view.J Cardiovasc Med (Hagerstown)2008;9:85-8

[47] Jabagi H,So D,Rubens FD.Native coronary disease progression post coronary artery bypass grafting.Cardiovasc Revasc Med2020;21:295-302

[48] Dimitrova KR,Geller CM,Ko W.Arterial grafts protect the native coronary vessels from atherosclerotic disease progression.Ann Thorac Surg2012;94:475-81

[49] Yoon SH,Yang DH.Risk of new native-vessel occlusion After Coronary Artery Bypass Grafting.Am J Cardiol2017;119:7-13

[50] Inci S,Bakirci EM,Gundogdu F.Predictors of reintervention after coronary artery bypass grafting.Eur Rev Med Pharmacol Sci2014;18:66-70

[51] Valooran GJ,Chandrasekharan K.Strategies for the coronary surgeon to remain "competitive and co-operative" in the PCI era.Indian Heart J2015;67:351-8 PMCID:PMC4561793

[52] Gaudino M,Benedetto U.ATLANTIC (Arterial Grafting International Consortium) AllianceMechanisms, consequences, and prevention of coronary graft failure.Circulation2017;136:1749-64

[53] Gigante C,Sonck J.Graft patency and progression of coronary artery disease after CABG assessed by angiography-derived fractional flow reserve.Int J Cardiol2020;316:19-25

[54] Shah PJ,Fuller J.Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999.J Thorac Cardiovasc Surg2003;126:1972-7

[55] Hess CN,Gibson CM.Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.Circulation2014;130:1445-51 PMCID:PMC4206593

[56] Valdes PJ,Lin JC. Vein graft stenosis. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499947/ [Last accessed on 13 Jul 2021]

[57] Morrison DA,Sacks J.Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia.J Am Coll Cardiol2002;40:1951-4

[58] Iqbal J,Kontopantelis E.British Cardiovascular Intervention Society (BCIS) and National Institute of Cardiovascular Outcome Research (NICOR)Choice of stent for percutaneous coronary intervention of saphenous vein grafts.Circ Cardiovasc Interv2017;10:e004457

[59] Giustino G,Sabik JF 3rd.Mortality after repeat revascularization following PCI or CABG for left main disease: the EXCEL trial.JACC Cardiovasc Interv2020;13:375-87

[60] Locker C,Bell MR.Repeat coronary bypass surgery or percutaneous coronary intervention after previous surgical revascularization.Mayo Clin Proc2019;94:1743-52